Blueshift Asset Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 82.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,934 shares of the company’s stock after selling 18,881 shares during the period. Blueshift Asset Management LLC’s holdings in Johnson & Johnson were worth $648,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Colony Group LLC raised its position in shares of Johnson & Johnson by 5.0% during the 1st quarter. Colony Group LLC now owns 107,624 shares of the company’s stock valued at $17,688,000 after buying an additional 5,122 shares in the last quarter. Clarius Group LLC raised its position in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Clarius Group LLC now owns 27,970 shares of the company’s stock valued at $4,608,000 after buying an additional 934 shares in the last quarter. Hudson Portfolio Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $1,201,000. Eukles Asset Management raised its position in Johnson & Johnson by 17.6% in the 2nd quarter. Eukles Asset Management now owns 10,601 shares of the company’s stock worth $1,746,000 after purchasing an additional 1,587 shares during the period. Finally, Cooke & Bieler LP raised its position in Johnson & Johnson by 3.9% in the 2nd quarter. Cooke & Bieler LP now owns 744,378 shares of the company’s stock worth $122,629,000 after purchasing an additional 28,195 shares during the period. 67.29% of the stock is owned by hedge funds and other institutional investors.
Shares of JNJ opened at $159.20 on Thursday. The firm’s 50-day moving average price is $168.96 and its 200-day moving average price is $167.54. The firm has a market capitalization of $419.09 billion, a price-to-earnings ratio of 23.94, a PEG ratio of 2.23 and a beta of 0.71. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $179.92.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Tuesday, August 24th were paid a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date of this dividend was Monday, August 23rd. Johnson & Johnson’s payout ratio is 52.80%.
A number of brokerages recently commented on JNJ. SVB Leerink reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Morgan Stanley cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price on the stock. in a research report on Tuesday, September 7th. Finally, Wells Fargo & Company reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, October 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $190.38.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
See Also: Call Option
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.